Delving into the Latest Updates on Ebola Sudan vaccine(Albert B. Sabin Vaccine Institute) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine(Albert B. Sabin Vaccine Institute), cAD3-Sudan Vaccine(Albert B. Sabin Vaccine Institute)

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Ebola Sudan virus disease

Inactive Indication-

Originator Organization

Albert B. Sabin Vaccine Institute, Inc.

Active Organization

Albert B. Sabin Vaccine Institute, Inc.

Biomedical Advanced Research and Development Authority (BARDA)

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

As foodstuffs adulterated by illegal dyes, such as Sudan I, II, III IIV, para-Red, have appeared on the European Union market, the emergency measures to eliminate this problem have been taken. The illegal dyes are added to dried, ground chilli, curry, curcuma and to palm oil. These products are imported from countries outside the E.U. The adulteration concerns also ready to eat products which contain the ingredients mentioned above. Apart from the adulteration, the presence of illegal dyes in foodstuffs can be a threat to consumer's health. In 2003-2005 three Commission Decisions on emergency measures regarding some products which can contain illegal dyes were published. Since May 2003 to March 2006, 651 notifications on food adulteration by illegal dyes were sent to the RASFF system. As a result of the taken measures, the number of notifications have decreased. The possibility of food adulteration by illegal dyes different from the ones which are used now are considered. This is the reason why the continuation of food control and cooperation between official control authorities and food producers are necessary.

01 Jan 1974·Godisen zbornik na Medicinskiot fakultet vo Skopje

[Microelectrophoretic method for determination of the serum lipoproteins].

Article

Author: Babamova-Vilarova, A

A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure

Author: Geisbert, Thomas W ; Geisbert, Joan B ; Ploquin, Aurélie ; Sullivan, Nancy J ; Johnson, Joshua C ; Trefry, John C ; Stanley, Daphne A ; Moliva, Juan I ; Honko, Anna N ; Wollen-Roberts, Suzanne E ; Dulan, Caitlyn N M ; Foulds, Kathryn E ; Carr, Derick ; Murray, Tamar ; Hunegnaw, Ruth

AbstractInfection with Sudan virus (SUDV) is characterized by an aggressive disease course with case fatality rates between 40-100% and no approved vaccines or therapeutics. SUDV causes sporadic outbreaks in sub-Saharan Africa, including a recent outbreak in Uganda which has resulted in over 100 confirmed cases in one month. Prior vaccine and therapeutic efforts have historically prioritized Ebola virus (EBOV), leading to a significant gap in available treatments. Two vaccines, Erbevo®and Zabdeno®/Mvabea®, are licensed for use against EBOV but are ineffective against SUDV. Recombinant adenovirus vector vaccines have been shown to be safe and effective against filoviruses, but efficacy depends on having low seroprevalence to the vector in the target human population. For this reason, and because of an excellent safety and immunogenicity profile, ChAd3 was selected as a superior vaccine vector. Here, a ChAd3 vaccine expressing the SUDV glycoprotein (GP) was evaluated for immunogenicity and efficacy in nonhuman primates. We demonstrate that a single dose of ChAd3-SUDV confers acute and durable protection against lethal SUDV challenge with a strong correlation between the SUDV GP-specific antibody titers and survival outcome. Additionally, we show that a bivalent ChAd3 vaccine encoding the GP from both EBOV and SUDV protects against both parenteral and aerosol lethal SUDV challenge. Our data indicate that the ChAd3-SUDV vaccine is a suitable candidate for a prophylactic vaccination strategy in regions at high risk of filovirus outbreaks.One Sentence Summary:A single-dose of ChAd3 vaccine protected macaques from lethal challenge with Sudan virus (SUDV) by parenteral and aerosol routes of exposure.

100 Deals associated with Ebola Sudan vaccine(Albert B. Sabin Vaccine Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ebola Sudan virus disease	Phase 2	Uganda	Albert B. Sabin Vaccine Institute, Inc.	15 Jul 2024
Ebola Sudan virus disease	Phase 2	Kenya	Albert B. Sabin Vaccine Institute, Inc.	15 Jul 2024